Solid Organ Transplant Segment to Dominate the Organ Transplant Diagnostics Market (by Transplant Type) The solid organ transplant segment is expected to dominate the organ transplant diagnostics ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

The comedian Drew Lausch relayed a story about his recent hookup with a doctor (OK brag) and what the experience taught him ...

About 1,200 B.C. LifeLabs employees have been on rotating strikes since Feb. 16. On Monday, four of 10 locations in or near ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Quest Diagnostics , a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians ...

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting ...